Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
Ventyx Biosciences, Inc. (VTYX)
Company Research
Source: GlobeNewswire
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease. “We are excited to initiate this trial of VTX3232 in patients with early Parkinson’s disease,” said Mark Forman, MD, PhD, Chief Medical Officer. “There is a compelling body of evidence from the literature suggesting a strong mechanistic rationale for targeting NLRP3-driven neuroinflammation in Parkinson’s disease and that microglial NLRP3 activation may play an important role in Parkinson’s disease pathogenesis and neurodegeneration. This trial will evaluate the effects of VTX3232 on disease- and target-relevant biomarkers and will also include exploratory PET neuroimaging to measure the
Show less
Read more
Impact Snapshot
Event Time:
VTYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTYX alerts
High impacting Ventyx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
VTYX
News
- Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Ventyx Biosciences Announces $27 Million Strategic Investment from SanofiGlobeNewswire
- Ventyx Biosciences Announces Departure of Chief Financial OfficerGlobeNewswire
- Ventyx Biosciences to Participate in Two Upcoming Investor ConferencesGlobeNewswire
- Ventyx Biosciences, Inc. (NASDAQ: VTYX) had its price target lowered by analysts at Wells Fargo & Company from $16.00 to $11.00. They now have an "overweight" rating on the stock.MarketBeat
VTYX
Earnings
- 8/8/24 - Beat
VTYX
Sec Filings
- 9/23/24 - Form 8-K
- 9/9/24 - Form 3
- 8/30/24 - Form 8-K
- VTYX's page on the SEC website